Core Viewpoint - Gilead Sciences has experienced a decline in stock performance recently, and various factors, including earnings estimates and revenue growth, will influence its future stock trajectory [2][5][11]. Earnings Estimate Revisions - Gilead is projected to report earnings of $1.99 per share for the current quarter, reflecting a year-over-year decrease of 1% [5]. - The consensus earnings estimate for the current fiscal year is $7.91, indicating a significant year-over-year increase of 71.2% [5]. - For the next fiscal year, the consensus estimate is $8.39, representing a year-over-year growth of 6.1% [6]. - The Zacks Rank for Gilead is 3 (Hold), indicating a neutral outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for Gilead in the current quarter is $7 billion, showing a year-over-year increase of 0.6% [11]. - Revenue estimates for the current and next fiscal years are $28.51 billion (a decrease of 0.8%) and $29.78 billion (an increase of 4.5%), respectively [11]. Last Reported Results and Surprise History - Gilead reported revenues of $6.67 billion in the last quarter, which is a year-over-year decline of 0.3% [12]. - The EPS for the last reported quarter was $1.81, compared to -$1.32 a year ago, with a revenue surprise of -2.46% and an EPS surprise of -0.55% [12]. - Over the last four quarters, Gilead has surpassed consensus EPS estimates three times and revenue estimates three times [13]. Valuation - Gilead's valuation metrics, including price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), are essential for assessing whether the stock is fairly valued [14][15]. - The Zacks Value Style Score for Gilead is graded B, indicating that the stock is trading at a discount compared to its peers [17].

GE Vernova (GEV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this the energy business spun off from General Electric have returned +21.2% over the past month versus the Zacks S&P 500 composite's -0.8% change. The Zacks Alternative Energy - Other industry, to which GE Vernova belongs, has gained 2.8% over this period. Now the key question is: Where could the stock ...

Grab Holdings Limited (GRAB) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this company have returned -2.5% over the past month versus the Zacks S&P 500 composite's -4.8% change. The Zacks Internet - Software industry, to which Grab belongs, has lost 9.1% over this period. Now the key question is: Where could the stock be headed in the near term?Althoug ...

Core Viewpoint - Owens Corning (OC) has been experiencing notable stock performance fluctuations, with recent trends indicating potential challenges ahead for the company in the near term [1][2]. Earnings Estimates - For the current quarter, Owens Corning is projected to report earnings of $2.82 per share, reflecting a year-over-year decline of -21.5% [5]. - The consensus earnings estimate for the current fiscal year stands at $14.10, indicating a year-over-year decrease of -11.4% [5]. - For the next fiscal year, the consensus earnings estimate is $15.10, which represents an increase of +7.1% compared to the previous year [6]. - The Zacks Rank for Owens Corning is 4 (Sell), indicating a negative outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $2.52 billion, which indicates a year-over-year growth of +9.4% [11]. - For the current fiscal year, the sales estimate is $10.58 billion, reflecting a decrease of -3.6%, while the estimate for the next fiscal year is $10.72 billion, indicating a slight increase of +1.4% [11]. Last Reported Results and Surprise History - In the last reported quarter, Owens Corning achieved revenues of $2.84 billion, marking a year-over-year increase of +23.3% [12]. - The earnings per share (EPS) for the same period was $3.22, slightly up from $3.21 a year ago [12]. - The company has consistently beaten consensus EPS estimates in the last four quarters and has exceeded revenue estimates three times during this period [13]. Valuation - Owens Corning is graded B on the Zacks Value Style Score, suggesting that the stock is trading at a discount compared to its peers [17].

Ares Capital (ARCC) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this private equity firm have returned -9.8%, compared to the Zacks S&P 500 composite's -8.9% change. During this period, the Zacks Financial - SBIC & Commercial Industry industry, which Ares Capital falls in, has lost 10.3%. The key question now is: What could be th ...

Core Viewpoint - Deckers (DECK) has experienced a stock return of -8.8% over the past month, underperforming the Zacks S&P 500 composite's -3.9% change and the Zacks Retail - Apparel and Shoes industry's -8.9% loss, raising questions about its near-term performance [1] Earnings Estimates Revisions - For the current quarter, Deckers is expected to post earnings of $0.55 per share, reflecting a decrease of -33.7% from the same quarter last year, with the Zacks Consensus Estimate changing by -2.4% over the last 30 days [4] - The consensus earnings estimate for the current fiscal year is $5.88, indicating a year-over-year increase of +21%, with a recent change of -1.2% [4] - For the next fiscal year, the consensus estimate is $6.52, suggesting an increase of +11% from the previous year, with a change of -1.2% over the past month [5] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $983.39 million, indicating a year-over-year growth of +2.5% [9] - For the current fiscal year, the revenue estimate is $4.95 billion, reflecting a growth of +15.4%, while the next fiscal year's estimate of $5.42 billion indicates a change of +9.6% [9] Last Reported Results and Surprise History - Deckers reported revenues of $1.83 billion in the last quarter, representing a year-over-year increase of +17.1%, with an EPS of $3 compared to $2.52 a year ago [10] - The reported revenues exceeded the Zacks Consensus Estimate of $1.71 billion by +6.7%, and the EPS surprise was +15.38% [10] - The company has consistently beaten consensus EPS and revenue estimates in the trailing four quarters [11] Valuation - Deckers is graded C in the Zacks Value Style Score, indicating it is trading at par with its peers [15] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for determining whether the stock is fairly valued, overvalued, or undervalued [13][14] Bottom Line - The Zacks Rank 3 suggests that Deckers may perform in line with the broader market in the near term, despite the market buzz surrounding the company [16]

Core Viewpoint - Allstate has recently gained attention as one of the most searched stocks, with a notable performance compared to the broader market and its industry [1][2]. Earnings Estimate Revisions - For the current quarter, Allstate is expected to report earnings of $3.98 per share, reflecting a decrease of -22.4% year-over-year, with a consensus estimate change of -3.8% over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $18.62, indicating a slight increase of +1.6% from the previous year, with a minor change of -0.2% in the last month [5]. - For the next fiscal year, the earnings estimate is $21.64, suggesting a growth of +16.2% year-over-year, with an increase of +1.8% in the past month [6]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $17.13 billion, representing a year-over-year increase of +11% [9]. - For the current fiscal year, the revenue estimates are $69.64 billion and $74.95 billion for the next fiscal year, indicating changes of +8.3% and +7.6%, respectively [9]. Last Reported Results and Surprise History - In the last reported quarter, Allstate achieved revenues of $16.71 billion, a year-over-year increase of +12.1%, with an EPS of $7.67 compared to $5.82 a year ago [10]. - The reported revenues were in line with the Zacks Consensus Estimate, showing a surprise of -0.01%, while the EPS surprise was +17.82% [11]. - Allstate has consistently beaten consensus EPS estimates in the last four quarters and topped revenue estimates three times during this period [11]. Valuation - Allstate is graded A in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [15]. - The evaluation of valuation multiples such as P/E, P/S, and P/CF is essential to determine if the stock is fairly valued, overvalued, or undervalued [13][14]. Conclusion - The current Zacks Rank of 3 suggests that Allstate may perform in line with the broader market in the near term, despite the market buzz surrounding the stock [16].

Core Viewpoint - Adma Biologics has shown strong stock performance recently, significantly outperforming the broader market and its industry, raising questions about its future trajectory [2][16]. Earnings Estimate Revisions - For the current quarter, Adma Biologics is expected to report earnings of $0.16 per share, reflecting a 100% increase year-over-year, with a 6.7% upward revision in estimates over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $0.71, indicating a 44.9% year-over-year increase, with a 3.7% upward revision in the last month [5]. - For the next fiscal year, the consensus estimate is $0.93, representing a 31% increase from the previous year, with a 6.9% upward revision [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), indicating a positive outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, showing a year-over-year increase of 45.5% [9]. - For the current fiscal year, the sales estimate is $495.8 million, indicating a 16.3% increase, while the next fiscal year's estimate is $611.5 million, reflecting a 23.3% increase [9]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics achieved revenues of $117.55 million, a 59.1% year-over-year increase, and an EPS of $0.14 compared to $0.04 a year ago [11]. - The company exceeded consensus revenue estimates in all four of the last quarters and surpassed EPS estimates three times [11]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [15].

Core Viewpoint - Boston Scientific (BSX) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimates Revisions - For the current quarter, Boston Scientific is expected to report earnings of $0.67 per share, reflecting a year-over-year increase of +19.6% [5] - The Zacks Consensus Estimate for the current fiscal year is $2.85, indicating a +13.6% change from the previous year, with a +2.7% increase in estimates over the last 30 days [5] - For the next fiscal year, the consensus estimate is $3.23, showing a +13.2% change from the prior year, with a +2.2% increase in estimates over the past month [6] - The Zacks Rank for Boston Scientific is 2 (Buy), suggesting a positive outlook based on recent earnings estimate revisions [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.56 billion, indicating a year-over-year increase of +18.2% [9] - For the current fiscal year, the sales estimate is $19.05 billion, reflecting a +13.8% change, while the next fiscal year's estimate is $21 billion, indicating a +10.2% change [9] Last Reported Results and Surprise History - Boston Scientific reported revenues of $4.56 billion in the last quarter, representing a +22.4% year-over-year change [10] - The reported EPS was $0.70, compared to $0.55 a year ago, with a revenue surprise of +3.52% and an EPS surprise of +7.69% [11] - The company has consistently beaten consensus EPS and revenue estimates over the last four quarters [11] Valuation - Boston Scientific has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [15]

Core Viewpoint - Allstate's stock has shown a positive return of +3.4% over the past month, contrasting with the S&P 500's decline of -4.1%, indicating potential resilience in its performance [1] Earnings Estimate Revisions - For the current quarter, Allstate is expected to report earnings of $4 per share, reflecting a decrease of -22% year-over-year, with the consensus estimate dropping by -23.6% in the last 30 days [4] - The consensus earnings estimate for the current fiscal year is $18.65, indicating a slight increase of +1.8% from the previous year, with a minor change of -0.6% over the last month [4] - For the next fiscal year, the consensus estimate is $21.61, suggesting a growth of +15.9% compared to the previous year, with a recent increase of +4.1% [5] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $17.13 billion, representing a year-over-year increase of +11% [8] - For the current fiscal year, the revenue estimate is $69.64 billion, indicating a growth of +8.3%, while the next fiscal year's estimate is $74.95 billion, reflecting a +7.6% change [8] Last Reported Results and Surprise History - In the last reported quarter, Allstate achieved revenues of $16.71 billion, marking a year-over-year increase of +12.1%, with an EPS of $7.67 compared to $5.82 a year ago [9] - The reported revenues were in line with the Zacks Consensus Estimate, showing a surprise of -0.01%, while the EPS surprise was +17.82% [10] - Allstate has consistently beaten consensus EPS estimates in the last four quarters and has topped revenue estimates three times during this period [10] Valuation - Allstate is graded A in the Zacks Value Style Score, indicating that it is trading at a discount compared to its peers [14]